126 related articles for article (PubMed ID: 2703841)
1. Humoral immune response in patients with cerebral parenchymal cysticercosis treated with praziquantel.
Estañol B; Juárez H; Irigoyen Mdel C; González-Barranco D; Corona T
J Neurol Neurosurg Psychiatry; 1989 Feb; 52(2):254-7. PubMed ID: 2703841
[TBL] [Abstract][Full Text] [Related]
2. [Integrity of the blood-brain barrier and intrathecal synthesis of IgG in parenchymatous and subarachnoid cerebral cysticercosis].
Estañol Vidal B; Díaz Granados J; Corona Vázquez T
Rev Invest Clin; 1989; 41(4):327-30. PubMed ID: 2631167
[TBL] [Abstract][Full Text] [Related]
3. [Cerebral cysticercosis. A report on the treatment with praziquantel].
Meyer-Wahl JG; Maier-Metz F
Fortschr Med; 1984 Mar; 102(12):336-9. PubMed ID: 6714907
[TBL] [Abstract][Full Text] [Related]
4. [A cerebrospinal fluid syndrome in neurocysticercosis].
Livramento JA
Arq Neuropsiquiatr; 1987 Sep; 45(3):261-75. PubMed ID: 2449880
[TBL] [Abstract][Full Text] [Related]
5. [Determination of praziquantel levels in cerebrospinal fluid and plasma in patients with cysticercosis of the central nervous system treated with praziquantel].
Jia JY
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1991 Jun; 24(3):174-6, 189-90. PubMed ID: 1889331
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of humoral immune components in human cysticercosis.
Correa D; Dalma D; Espinoza B; Plancarte A; Rabiela MT; Madrazo I; Gorodezky C; Flisser A
J Parasitol; 1985 Oct; 71(5):535-41. PubMed ID: 3903094
[TBL] [Abstract][Full Text] [Related]
7. Serum and CSF immunological findings in ALS.
Apostolski S; Nikolić J; Bugarski-Prokopljević C; Miletić V; Pavlović S; Filipović S
Acta Neurol Scand; 1991 Feb; 83(2):96-8. PubMed ID: 2017904
[TBL] [Abstract][Full Text] [Related]
8. Cerebral cysticercosis: treatment with praziquantel. Report of two cases.
Markwalder K; Hess K; Valavanis A; Witassek F
Am J Trop Med Hyg; 1984 Mar; 33(2):273-80. PubMed ID: 6711744
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous and cerebral cysticercosis treated with praziquantel.
Quimosing EM; Conde J; Cross JH
Southeast Asian J Trop Med Public Health; 1984 Jun; 15(2):201-5. PubMed ID: 6505787
[TBL] [Abstract][Full Text] [Related]
10. Clinical and immunologic follow-up study of patients with neurocysticercosis after treatment with praziquantel.
Rolfs A; Mühlschlegel F; Jansen-Rosseck R; Martins AR; Bedaque EA; Tamburus WM; Pedretti L; Schulte G; Feldmeier H; Kremsner P
Neurology; 1995 Mar; 45(3 Pt 1):532-8. PubMed ID: 7898711
[TBL] [Abstract][Full Text] [Related]
11. Anticysticercous antibodies in serum and cerebrospinal fluid in patients with cerebral cysticercosis.
Corona T; Pascoe D; González-Barranco D; Abad P; Landa L; Estañol B
J Neurol Neurosurg Psychiatry; 1986 Sep; 49(9):1044-9. PubMed ID: 3760893
[TBL] [Abstract][Full Text] [Related]
12. [ELISA (IgG and IgM) of the CSF and serum in neurocysticercosis under treatment with praziquantel: comparison with complement fixation reactions and immunofluorescence].
Livramento JA; Costa JM; Machado LR; Nóbrega JP; Spina-França A
Arq Neuropsiquiatr; 1985 Sep; 43(3):267-74. PubMed ID: 3911928
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of the therapeutic efficacy of praziquantel against human cysticercosis.
Rim HJ; Joo KH
Acta Leiden; 1989; 57(2):235-45. PubMed ID: 2489002
[TBL] [Abstract][Full Text] [Related]
14. Immune complexes and the complement factors C4 and C3 in cerebrospinal fluid and serum from patients with chronic progressive multiple sclerosis.
Jans H; Heltberg A; Zeeberg I; Kristensen JH; Fog T; Raun NE
Acta Neurol Scand; 1984 Jan; 69(1):34-8. PubMed ID: 6702418
[TBL] [Abstract][Full Text] [Related]
15. Immune complexes in serum and in cerebrospinal fluid in African trypanosomiasis. Correlation with polyclonal B cell activation and with intracerebral immunoglobulin synthesis.
Lambert PH; Berney M; Kazyumba G
J Clin Invest; 1981 Jan; 67(1):77-85. PubMed ID: 6969733
[TBL] [Abstract][Full Text] [Related]
16. Therapy of parenchymal brain cysticercosis with praziquantel.
Sotelo J; Escobedo F; Rodriguez-Carbajal J; Torres B; Rubio-Donnadieu F
N Engl J Med; 1984 Apr; 310(16):1001-7. PubMed ID: 6708975
[TBL] [Abstract][Full Text] [Related]
17. Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis.
Sotelo J; del Brutto OH; Penagos P; Escobedo F; Torres B; Rodriguez-Carbajal J; Rubio-Donnadieu F
J Neurol; 1990 Apr; 237(2):69-72. PubMed ID: 2192018
[TBL] [Abstract][Full Text] [Related]
18. Neurocysticercosis: surgical and medical management with praziquantel.
Leblanc R; Knowles KF; Melanson D; MacLean JD; Rouleau G; Farmer JP
Neurosurgery; 1986 Apr; 18(4):419-27. PubMed ID: 3703211
[TBL] [Abstract][Full Text] [Related]
19. Cerebral cysticercosis in a European patient: problems of disease activity and therapeutic implications.
Thie A; Lachenmayer L; Bialek R; Kunze K
Klin Wochenschr; 1987 May; 65(10):475-9. PubMed ID: 3599795
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of praziquantel therapy in neurocysticercosis.
Robles C; Sedano AM; Vargas-Tentori N; Galindo-Virgen S
J Neurosurg; 1987 Mar; 66(3):359-63. PubMed ID: 3819831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
